(1888PressRelease)
June 15, 2009 - The bacterium Streptococcus pneumoniae is a serious cause of illness and death and a major etiologic agent of community-acquired pneumonia, meningitis, and acute otitis media. Pneumococcal resistance to antimicrobial drugs (including β-lactams, macrolides, tetracycline, and cotrimoxazole) has become a worldwide problem.
Financial Business Solutions Worldwide has identified this as a major need in correction, and has affirmed the private sectors commitment to the combat of these types of diseases.
New fluoroquinolones are being used as therapeutic alternatives for treatment of adult patients with community-acquired pneumonia. Resistance to fluoroquinolones in S. pneumoniae can be acquired by point mutations, intraspecific recombination or interspecific recombination with the S. mitis group.
FBSW Officials identified that particular aspects were at work in the resistance to introduced technology and has affirmed the need to have further reseach on DNA topology.
Resistance is caused mainly by amino acid changes in quinolone resistance–determining regions (QRDRs) of the subunits of DNA topoisomerase IV (topo IV; parC2 and parE2) and DNA gyrase (gyrA2 and gyrB2) enzymes that control DNA topology. In addition, fluoroquinolone efflux also contributes to resistance. Genetic and biochemical studies have shown that for most fluoroquinolones, such as ciprofloxacin and levofloxacin, topo IV and gyrase are primary and secondary targets, respectively (9–13). However, gyrase is the primary target for moxifloxacin.
Although current prevalence of fluoroquinolone resistance in pneumococci is
###
